Dr. Chi on Androgen Deprivation Therapy for High-Risk Metastatic Hormone-Naive Prostate Cancer

Kim Chi, MD
Published: Monday, Jun 19, 2017



Kim Chi, MD, associate director of clinical research, Vancouver Prostate Centre, professor, Department of Medicine, University of British Columbia, discusses androgen deprivation therapy (ADT) with abiraterone acetate (Zytiga) plus prednisone or placebo in patients with high-risk metastatic hormone-naïve prostate cancer.

In addition to the LATITUDE trial showing positive results for ADT with abiraterone acetate plus prednisone or placebo, the STAMPEDE study also showed positive results for the ADT, explains Chi.

A remaining question with this therapy is if it should always be treated in combination with abiraterone due to less toxicity, states Chi.
 
SELECTED
LANGUAGE


Kim Chi, MD, associate director of clinical research, Vancouver Prostate Centre, professor, Department of Medicine, University of British Columbia, discusses androgen deprivation therapy (ADT) with abiraterone acetate (Zytiga) plus prednisone or placebo in patients with high-risk metastatic hormone-naïve prostate cancer.

In addition to the LATITUDE trial showing positive results for ADT with abiraterone acetate plus prednisone or placebo, the STAMPEDE study also showed positive results for the ADT, explains Chi.

A remaining question with this therapy is if it should always be treated in combination with abiraterone due to less toxicity, states Chi.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Publication Bottom Border
Border Publication
x